EdiTy Therapeutics

About EdiTy Therapeutics

EdiTy Therapeutics utilizes engineered immune cells to deliver therapeutic proteins directly into the cytoplasm of diseased cells, enabling intracellular reprogramming for conditions such as cancer and genetic disorders. This approach overcomes limitations of existing therapies by targeting specific tissues and facilitating protein replacement, genetic correction, and modulation of disease pathways.

```xml <problem> Current therapeutic approaches face limitations in tissue tropism, toxicity, and payload size when targeting intracellular proteins, which constitute a significant portion of the body's proteins and key disease pathway targets. Existing technologies struggle to introduce functional proteins into specific cells or tissues, hindering effective treatment of various diseases. </problem> <solution> Edity Therapeutics is developing a platform that leverages engineered immune cells to deliver therapeutic proteins directly into the cytoplasm of diseased cells, enabling intracellular reprogramming. The technology integrates therapeutic proteins into the perforin-granzyme pathway for targeted delivery to the cytosol of target cells. By redesigning immune cells to deliver protein therapeutics, Edity aims to address previously inaccessible intracellular targets and modulate disease pathways through protein replacement, target modulation, genetic correction, and protein gain of function. The platform is designed to work with T-cells and NK cells and can use CAR, TCR, or similar modalities for homing and activation. </solution> <features> - Engineered immune cells for targeted delivery of therapeutic proteins into the cytoplasm of diseased cells. - Integration of therapeutic proteins into the perforin-granzyme pathway for direct delivery to the cytosol. - Compatible with allogeneic approaches. - Can be used with T-cells and NK cells. - Utilizes CAR, TCR, or similar modalities for homing and activation. - AI-designed pro-inflammatory proteins to reprogram the tumor microenvironment. </features> <target_audience> The primary target audience includes researchers and clinicians focused on developing novel therapies for cancer, genetic disorders, and regenerative medicine, as well as pharmaceutical companies seeking innovative drug delivery platforms. </target_audience> ```

What does EdiTy Therapeutics do?

EdiTy Therapeutics utilizes engineered immune cells to deliver therapeutic proteins directly into the cytoplasm of diseased cells, enabling intracellular reprogramming for conditions such as cancer and genetic disorders. This approach overcomes limitations of existing therapies by targeting specific tissues and facilitating protein replacement, genetic correction, and modulation of disease pathways.

Where is EdiTy Therapeutics located?

EdiTy Therapeutics is based in Ho, Israel.

When was EdiTy Therapeutics founded?

EdiTy Therapeutics was founded in 2020.

How much funding has EdiTy Therapeutics raised?

EdiTy Therapeutics has raised $13.6M.

Location
Ho, Israel
Founded
2020
Funding
$13.6M
Employees
22 employees
Investors
TAL Ventures
ET

EdiTy Therapeutics

EdiTy Therapeutics utilizes engineered immune cells to deliver therapeutic proteins directly into the cytoplasm of diseased cells, enabling intracellular reprogramming for conditions such as cancer and genetic disorders. This approach overcomes limitations of existing therapies by targeting specific tissues and facilitating protein replacement, genetic correction, and modulation of disease pathways.

Ho, IsraelFounded 2020221K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 3 months ago

Funding

$13.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Current therapeutic approaches face limitations in tissue tropism, toxicity, and payload size when targeting intracellular proteins, which constitute a significant portion of the body's proteins and key disease pathway targets. Existing technologies struggle to introduce functional proteins into specific cells or tissues, hindering effective treatment of various diseases.

Solution

Edity Therapeutics is developing a platform that leverages engineered immune cells to deliver therapeutic proteins directly into the cytoplasm of diseased cells, enabling intracellular reprogramming. The technology integrates therapeutic proteins into the perforin-granzyme pathway for targeted delivery to the cytosol of target cells. By redesigning immune cells to deliver protein therapeutics, Edity aims to address previously inaccessible intracellular targets and modulate disease pathways through protein replacement, target modulation, genetic correction, and protein gain of function. The platform is designed to work with T-cells and NK cells and can use CAR, TCR, or similar modalities for homing and activation.

Target Audience

The primary target audience includes researchers and clinicians focused on developing novel therapies for cancer, genetic disorders, and regenerative medicine, as well as pharmaceutical companies seeking innovative drug delivery platforms.

Features

  • Engineered immune cells for targeted delivery of therapeutic proteins into the cytoplasm of diseased cells.
  • Integration of therapeutic proteins into the perforin-granzyme pathway for direct delivery to the cytosol.
  • Compatible with allogeneic approaches.
  • Can be used with T-cells and NK cells.
  • Utilizes CAR, TCR, or similar modalities for homing and activation.
  • AI-designed pro-inflammatory proteins to reprogram the tumor microenvironment.
1
This profile is AI-generated and may contain inaccuracies.